Equities research analysts at RBC Capital raised their price target on shares of NuVasive (NASDAQ:NUVA) from $31.00 to $35.00 in a research note issued to investors on Friday, Analyst RN reports. The firm currently has a “sector perform” rating on the stock. RBC Capital’s price objective points to a potential upside of 6.42% from the company’s current price.
Shares of NuVasive (NASDAQ:NUVA) traded down 1.32% during mid-day trading on Friday, hitting $32.89. The stock had a trading volume of 467,882 shares. NuVasive has a 1-year low of $13.44 and a 1-year high of $33.88. The stock has a 50-day moving average of $27.39 and a 200-day moving average of $24.64. The company’s market cap is $1.467 billion.
NuVasive (NASDAQ:NUVA) last announced its earnings results on Tuesday, October 29th. The company reported $0.39 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.24 by $0.15. The company had revenue of $169.20 million for the quarter, compared to the consensus estimate of $158.30 million. During the same quarter last year, the company posted $0.23 earnings per share. NuVasive’s revenue was up 14.0% compared to the same quarter last year. Analysts expect that NuVasive will post $1.14 earnings per share for the current fiscal year.
In other NuVasive news, CEO Alexis Lukianov unloaded 5,000 shares of the stock on the open market in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $31.45, for a total value of $157,250.00. Following the completion of the sale, the chief executive officer now directly owns 72,827 shares in the company, valued at approximately $2,290,409. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
A number of other analysts have also recently weighed in on NUVA. Analysts at Needham & Company raised their price target on shares of NuVasive from $35.00 to $40.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Barclays raised their price target on shares of NuVasive from $28.00 to $30.00 in a research note to investors on Friday. They now have an “equal weight” rating on the stock. Finally, analysts at TheStreet upgraded shares of NuVasive from a “hold” rating to a “buy” rating in a research note to investors on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. NuVasive presently has a consensus rating of “Hold” and an average price target of $28.93.
NuVasive, Inc (NASDAQ:NUVA) is a medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.